Home Applications 125377 Application 125377
Type BLA
Sponsor BRISTOL MYERS SQUIBB Purple Book Biologic Products# BLA, Proprietary name, Proper name table BLA Proprietary name Proper name License type Status Latest source 125377 Yervoy ipilimumab 351(a) Rx 2026-07-01
Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 YERVOY IPILIMUMAB INJECTABLE; INJECTION 3MG No No
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 32 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 0003-2327 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2327 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2327 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2327 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2327 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2327 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2327 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2327 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2327 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2327 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2327 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2327 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2327 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2327 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2327 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2327 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2328 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2328 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2328 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2328 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2328 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2328 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2328 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2328 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2328 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2328 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2328 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2328 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2328 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2328 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2328 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current 0003-2328 YERVOY ipilimumab E.R. Squibb & Sons, L.L.C. BLA Current